An Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC

Condition:   Recurrent Basal Cell Carcinoma Interventions:   Drug: Patidegib Topical Gel, 2%;   Drug: Patidegib Topical Gel, Vehicle Sponsor:   PellePharm, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials